Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy
- Author(s)
- Radcliff, FJ; Caruso, DA; Koina, C; Riordan, MJ; Roberts, AW; Tang, MLK; Baum, CM; Woulfe, SL; Ashley, DM;
- Details
- Publication Year 2002-10,Volume 119,Issue #1,Page 204-211
- Journal Title
- BRITISH JOURNAL OF HAEMATOLOGY
- Publication Type
- Journal Article
- Abstract
- The number of dendritic cells (DC) circulating in the peripheral blood of cancer patients were monitored at multiple time points during chemotherapy and granulocyte colony-stimulating factor (G-CSF) support. DC were identified via the lack of expression of standard lineage markers and high expression of HLA-DR (LN-/DR+). The expression of DC-associated markers, including CD83, CD11c, IL-3Ra (CDw123) and CD86, within this LN-/DR+ population was also monitored. Maximal mobilization occurred during recovery on d 12, with a mean 32-fold increase in LN-/DR+ numbers. The most striking increase was observed in the LN-/DR+/CD83(+) cell population: 12 d after commencement of treatment, the proportion of these cells had increased by approximately 120-fold when compared with baseline. Peripheral blood mononuclear cell (PBMC) and CD34(+) cell numbers also peaked 12 d into the treatment regimen in most patients. These data suggest that it should be possible to acquire substantial numbers of DC from leukapheresis products collected from cancer patients undergoing a standard treatment regimen of chemotherapy and G-CSF. This strategy may be a feasible, low-risk means of acquiring cells for DC-based vaccine studies.
- Publisher
- BLACKWELL PUBLISHING LTD
- Keywords
- HIGH-DOSE CHEMOTHERAPY; BONE-MARROW TRANSPLANTATION; BLOOD PROGENITOR CELLS; PERIPHERAL-BLOOD; MONOCLONAL-ANTIBODY; GENERATION; RECOVERY; CMRF-44; DISEASE
- Publisher's Version
- https://doi.org/10.1046/j.1365-2141.2002.03717.x
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2002-10-01 12:00:00